Invasive Candidiasis

1. Clinical Overview

Summary

Invasive Candidiasis refers to Candida infection in the bloodstream (Candidemia) or deep-seated organ infection. It is a life-threatening, predominantly nosocomial (hospital-acquired) fungal infection with crude mortality rates of 40-55% in critically ill patients, and attributable mortality of approximately 20-25%. [13] The condition represents the 4th to 6th leading cause of nosocomial bloodstream infections in developed countries. [1]

Risk factors are ubiquitous in intensive care: broad-spectrum antibiotics, central venous catheters (CVCs), Total Parenteral Nutrition (TPN), abdominal surgery, neutropenia, immunosuppression, renal replacement therapy, and prolonged ICU admission. [13] While Candida albicans remains the most common species (40-60%), non-albicans species (C. glabrata, C. parapsilosis, C. tropicalis, C. krusei) account for an increasing proportion, with significant implications for antifungal resistance. [20] The emergence of Candida auris represents a paradigm shift: multi-drug resistant, transmissible between patients, and persistent on environmental surfaces, this species poses unprecedented infection control challenges. [7]

Management centers on three pillars: early appropriate antifungal therapy (Echinocandins first-line), aggressive source control (CVC removal mandatory), and screening for metastatic complications (ophthalmology review for endophthalmitis). [2,10] Delays in any component significantly worsen outcomes. [13]

Clinical Pearls

Remove the Line: Central venous catheters are the most common source. Remove or exchange all CVCs in all patients with candidemia whenever feasible. CVC retention is associated with persistent fungemia and mortality. [19]

Eye Exam is Mandatory: All patients with candidemia need dilated fundoscopy (Ophthalmology) within 1 week of diagnosis. Candida endophthalmitis occurs in 3-15% of cases; visual loss is preventable with early detection and treatment. [10]

Persistent Fever on Antibiotics: In an ICU patient with fever unresponsive to broad-spectrum antibiotics for 3-5 days, empirical antifungal therapy should be strongly considered. Beta-D-glucan testing can guide decision-making. [16]

C. auris is Different: Multi-drug resistant, transmissible, and survives on surfaces for weeks. Requires strict contact precautions, dedicated equipment, and enhanced environmental cleaning. Infection control must be notified immediately. [7]

Duration: From First Negative Culture: Treatment duration for uncomplicated candidemia is 14 days from the first negative blood culture, not from initiation of therapy. Repeat blood cultures every 24-48 hours until clearance is documented. [2]

---

2. Epidemiology

Global Burden

• Hospital Incidence: 0.5-1.5 cases per 1,000 hospital admissions in tertiary centers. [13]
• ICU Prevalence: 5-10% of ICU patients develop invasive candidiasis; incidence up to 10-fold higher than general wards. [13]
• Crude Mortality: 40-55% overall mortality in ICU patients with candidemia. [13]
• Attributable Mortality: 20-25% directly attributable to Candida infection (after adjusting for underlying disease severity). [13]
• Time to Diagnosis: Median time from symptom onset to positive blood culture is 5-7 days, contributing to delayed treatment. [2]

Species Distribution and Regional Variation

The epidemiology of invasive candidiasis varies geographically and temporally, with important implications for empirical therapy:

Temporal Trends

• Non-albicans shift: Proportion of non-albicans species increased from 35% (1990s) to 50-60% (2020s), driven by C. glabrata in North America and C. parapsilosis in Europe. [20]
• C. auris emergence: First detected 2009; by 2024, reported in > 50 countries with sustained healthcare transmission. U.S. cases increased 200% between 2020-2023. [7]
• Echinocandin resistance: Emerging in C. glabrata (5-10% of isolates) and C. auris (10-15%), associated with prior echinocandin exposure and FKS gene mutations. [7,20]

Risk Factors

The following risk factors reflect the pathogenesis of candidemia: disruption of mucosal barriers, immunosuppression, and dysbiosis.

Candida Colonization Index

The Candida Colonization Index (ratio of colonized sites to sampled sites) > 0.5 predicts progression to invasive candidiasis in surgical ICU patients. However, routine surveillance cultures are not recommended outside research settings. [13]

---

3. Pathophysiology

From Commensal to Pathogen

Candida species are commensal organisms colonizing the gastrointestinal tract (40-80% of healthy adults), oropharynx (30-60%), vagina (20-30%), and skin (5-10%). The transition from benign colonization to life-threatening invasive infection requires:

1. Increased Fungal Burden: Antibiotic disruption of bacterial microbiome → loss of competitive inhibition → Candida overgrowth. [13]
2. Barrier Breach: Mucosal damage (chemotherapy, surgery), indwelling devices (CVCs, urinary catheters), or loss of skin integrity (burns, surgical incisions). [13]
3. Impaired Host Immunity: Neutropenia, corticosteroids, immunosuppressive medications, or critical illness-associated immunosuppression. [13]

Pathogenic Cascade

Stage 1: Barrier Breach and Bloodstream Entry

• CVC-Associated: Skin flora (especially C. parapsilosis) colonize catheter hub → biofilm formation on intraluminal surface → continual seeding into bloodstream. [19]
• Gastrointestinal Translocation: Mucosal disruption (surgery, chemotherapy, ischemia) → Candida penetrates intestinal epithelium → mesenteric lymphatics → portal/systemic circulation. [13]
• Surgical Source: Intra-abdominal candidiasis (peritonitis, abscess) → direct invasion into peritoneal vasculature.

Stage 2: Bloodstream Survival

• Immune Evasion: Candida spp. resist complement-mediated killing through expression of complement inhibitor proteins.
• Neutrophil Resistance: Biofilm-associated Candida are 10-1000x more resistant to neutrophil-mediated killing. [19]
• Platelet Interaction: Candida binds platelets, forming micro-aggregates that may facilitate tissue adhesion and dissemination.

Stage 3: Tissue Invasion and Metastatic Seeding

Hematogenous dissemination to:

• Eyes: Chorioretinitis and endophthalmitis (3-15% of candidemia cases). Risk highest with prolonged candidemia (> 48-72 hours). [10]
• Heart: Endocarditis (2-5%), especially on prosthetic valves or in IVDU. Large vegetations common; surgery often required. [2]
• Kidneys: Microabscesses (10-30% at autopsy). Usually clinically silent; may cause pyuria or renal failure.
• Liver/Spleen: Chronic disseminated candidiasis (hepatosplenic candidiasis) in neutropenic patients during immune reconstitution. Multiple microabscesses; prolonged therapy required. [2]
• Bone/Joint: Osteomyelitis, septic arthritis (especially vertebral in IVDU, or sternoclavicular joint post-cardiac surgery).
• CNS: Meningitis, brain abscess (less than 5%, but high mortality). More common in neonates.

Stage 4: Inflammatory Response and Organ Dysfunction

• Sepsis Syndrome: Fungal cell wall components (β-1,3-glucan, mannan, chitin) activate pattern recognition receptors (Toll-like receptors, Dectin-1) → pro-inflammatory cytokine release (TNF-α, IL-6, IL-1β) → systemic inflammation, vasodilation, capillary leak. [13]
• Coagulopathy: Candida induces tissue factor expression → activation of coagulation cascade → disseminated intravascular coagulation (DIC) in severe cases.
• Multi-Organ Dysfunction: Sepsis-induced hypotension, acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), hepatic dysfunction.

Virulence Factors

---

4. Clinical Presentation

Cardinal Features

Invasive candidiasis, particularly candidemia, often presents with non-specific signs of infection, mimicking bacterial sepsis. The key clinical challenge is distinguishing candidemia from bacterial or other fungal infections in critically ill patients with multiple confounders.

Symptoms

• Fever: Present in 70-90% of cases (persistent or intermittent). May be refractory to broad-spectrum antibiotics for 3-5 days. [13]
• Rigors/Chills: Common during candidemia episodes, especially with CVC manipulation (flushing lines).
• Sepsis Syndrome: Hypotension, tachycardia, tachypnea, altered mental status. Indistinguishable from bacterial sepsis clinically.
• Organ-Specific Symptoms (if metastatic infection):
  • "Eye: Blurred vision, floaters, eye pain, photophobia (endophthalmitis)."
  • "Heart: New or changing murmur, embolic phenomena (endocarditis)."
  • "Abdomen: Persistent peritonitis despite antibiotics post-abdominal surgery."
  • "Bone/Joint: Localized pain, swelling (vertebral osteomyelitis, septic arthritis)."

Signs

Clinical Syndromes of Invasive Candidiasis

1. Candidemia (Primary Bloodstream Infection)

• Most common form (70-80% of invasive candidiasis). [13]
• Source: CVC-associated (40-60%), GI translocation (20-30%), unknown (20%).
• Presentation: Fever, sepsis, often without obvious focus.
• Blood Culture Sensitivity: 50-70% (single set); improves to 80-90% with multiple sets. [2]

2. Catheter-Associated Candidemia

• Accounts for 40-60% of candidemia cases. [13]
• Biofilm on catheter intraluminal surface serves as persistent source.
• CVC Removal is Mandatory: Retention associated with persistent fungemia (> 48 hours), relapse, and mortality. [19]
• Differential time to positivity (CVC vs peripheral blood cultures) may suggest catheter source, but is unreliable for Candida (unlike bacteria).

3. Intra-Abdominal Candidiasis

• Post-surgical peritonitis, pancreatic necrosis, anastomotic leak, perforated viscus.
• Isolated intra-abdominal Candida (without candidemia) in post-op patients: treat if high risk (recurrent GI perforation, immunosuppression). [2]
• May progress to candidemia in 5-20% if untreated.

4. Chronic Disseminated Candidiasis (Hepatosplenic Candidiasis)

• Population: Neutropenic patients (acute leukemia, hematopoietic stem cell transplant) during neutrophil recovery. [2]
• Pathophysiology: Candida seeds liver/spleen during neutropenia → microabscesses form during immune reconstitution → prolonged fever, alkaline phosphatase elevation.
• Imaging: CT/MRI shows multiple small (less than 1 cm) hypodense "bull's-eye" or "target" lesions in liver and spleen.
• Treatment: Prolonged antifungal therapy (months) until lesions resolve.

5. Candida Endocarditis

• Incidence: 2-5% of candidemia; accounts for less than 2% of all infective endocarditis. [2]
• Risk Factors: Prosthetic valves (60% of cases), IVDU, prolonged candidemia, prior cardiac surgery.
• Features: Large vegetations (> 10 mm), high embolic rate (50-60%), systemic emboli (CNS, spleen, kidneys).
• Mortality: 40-70% despite treatment.
• Management: Prolonged antifungal therapy (≥6 weeks) + valve replacement (surgery required in > 90% for cure). [2]

6. Candida Endophthalmitis

• Incidence: 3-15% of candidemia cases (varies by population and screening intensity). [10]
• Risk Factors: Duration of candidemia > 48-72 hours, neutropenia, ICU admission, immunosuppression.
• Types:
  • Chorioretinitis: Candida seeding of choroid/retina. Fluffy white/yellow retinal lesions ("cotton wool" appearance). May be asymptomatic initially.
  • "Endophthalmitis: Extension into vitreous. Vitreous haze, hypopyon, severe visual loss. Ophthalmology emergency."
• Diagnosis: Dilated fundoscopy by ophthalmology within 1 week of candidemia diagnosis. [10]
• Outcome: Vision loss in 30-50% of endophthalmitis cases despite treatment. Early detection critical. [10]

7. Other Metastatic Complications

• Osteomyelitis/Septic Arthritis: Vertebral (most common), sternoclavicular (IVDU, post-cardiac surgery), prosthetic joint.
• Meningitis: More common in neonates; rare in adults. CSF culture positive in less than 50%.
• Renal Abscess: Usually microabscesses; clinically silent. May cause persistent candiduria.

---

5. Differential Diagnosis

Invasive candidiasis presents as undifferentiated sepsis in critically ill patients. The differential is broad:

---

6. Investigations

Microbiological Diagnosis

Blood Cultures (Gold Standard)

• Essential: Obtain ≥2 sets (peripheral + CVC if present) before antifungal initiation. [2]
• Sensitivity: 50-70% (single set); 80-90% (≥2 sets over 24 hours). Lower sensitivity for deep-seated infection without candidemia.
• Time to Positivity: Median 2-3 days (range 1-5 days). Longer than bacterial cultures (12-24 hours).
• Species Identification: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) provides species ID within 24 hours from positive culture. Critical for guiding antifungal choice. [2]
• Repeat Cultures: Daily blood cultures until clearance documented (negative cultures). Time to clearance predicts prognosis. [2]

Antifungal Susceptibility Testing

• Perform for all Candida isolates from sterile sites. [2]
• Interpretation (Clinical and Laboratory Standards Institute, CLSI):
  • "C. albicans: 90% fluconazole-susceptible."
  • "C. glabrata: Intrinsic reduced fluconazole susceptibility (dose-dependent); emerging echinocandin resistance (FKS mutations)."
  • "C. parapsilosis: Usually azole-susceptible; higher echinocandin MICs (clinical significance debated)."
  • "C. krusei: Intrinsically fluconazole-resistant."
  • "C. auris: Multi-drug resistant: 90% fluconazole-resistant, 30% amphotericin-resistant, 5-10% echinocandin-resistant. [7]"

Biomarkers and Non-Culture Diagnostics

1,3-Beta-D-Glucan (BDG)

• Cell Wall Component: Present in Candida, Aspergillus, Pneumocystis. Not present in Mucorales or Cryptococcus.
• Sensitivity: 70-80% for invasive candidiasis (higher in candidemia than deep-seated infection). [16]
• Specificity: 60-80% (false positives: bacteremia, hemodialysis, IVIG, gauze exposure).
• Utility: Negative predictive value 95%; useful to rule out invasive fungal infection. Serial measurements: declining BDG associated with treatment response and reduced mortality. [16]
• Threshold: > 80 pg/mL (assay-dependent; check local lab).
• Timing: Rises earlier than positive blood cultures (2-3 days before); useful for empirical therapy decisions. [16]

Mannan and Anti-Mannan Antibodies

• Mannan: Candida cell wall polysaccharide (antigen). Detected early in infection.
• Anti-Mannan IgG: Antibody response (appears later).
• Combined Testing: Sensitivity 80-85%, specificity 85-90% when both used together.
• Availability: Limited; not widely used in clinical practice.

T2Candida Panel (T2MR)

• Rapid PCR-Based Blood Test: Detects Candida DNA directly from blood (no culture required). [2]
• Species Detected: C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. krusei.
• Turnaround Time: 3-5 hours (vs 2-5 days for culture).
• Sensitivity: 90% (higher than blood culture for candidemia).
• Specificity: 95%.
• Advantages: Earlier diagnosis, detects candidemia missed by culture.
• Limitations: Does not provide susceptibility testing. Does not detect C. auris. Expensive. Not universally available.

Imaging Studies

Indications

• Identify source of infection (intra-abdominal abscess, empyema).
• Detect metastatic complications (hepatosplenic abscesses, osteomyelitis, endocarditis).
• Evaluate deep-seated candidiasis in patients without candidemia.

CT Abdomen/Pelvis

• Hepatosplenic Candidiasis: Multiple small (less than 1 cm) hypodense "bull's-eye" lesions in liver/spleen. More conspicuous on MRI (T2 hyperintense). [2]
• Intra-Abdominal Abscesses: Fluid collections, peritoneal thickening.
• Timing: Consider if fever persists > 5 days despite antifungal therapy.

Echocardiography (TTE/TEE)

• Indication: New or changing murmur, embolic phenomena, persistent candidemia (> 72 hours), prosthetic valve, IVDU.
• TEE Superior to TTE: Sensitivity for vegetations 90-95% (TEE) vs 50-60% (TTE). [2]
• Findings: Large vegetations (often > 10 mm), valve perforation, abscess.

Ophthalmology Examination (Mandatory)

• Dilated Fundoscopy by Ophthalmologist: All patients with candidemia must undergo ophthalmology examination. [10]
• Timing: Within 1 week of candidemia diagnosis (ideally within 2-3 days of starting antifungals, after initial clinical stabilization). [10]
• Incidence of Ocular Involvement: Recent meta-analysis (2023) of 8,599 patients: ocular candidiasis in 8.2% (95% CI 6.5-10.2%), endophthalmitis (chorioretinitis + vitreous involvement) in 4.3% (95% CI 3.2-5.8%). [10]
• Rationale: Early endophthalmitis may be asymptomatic; delayed diagnosis leads to irreversible vision loss. [10]
• Findings:
  • "Chorioretinitis: Fluffy white/yellow retinal lesions (1-2 mm), often near retinal vessels. Macular involvement → central vision loss."
  • "Endophthalmitis: Vitreous haze, hypopyon, reduced visual acuity, eye pain."
• Frequency of Screening Debate: IDSA recommends ophthalmology exam for all; some European guidelines suggest risk-stratified approach (low risk if rapid clearance, no immunosuppression). However, meta-analysis supports universal screening given prevalence. [10]

---

7. Management

Management of invasive candidiasis rests on three pillars: early appropriate antifungal therapy, aggressive source control, and identification/treatment of metastatic complications.

Management Algorithm

     SUSPECTED INVASIVE CANDIDIASIS
     (Risk factors + Fever unresponsive to antibiotics 3-5 days)
                      ↓
     IMMEDIATE ACTIONS:
     • Blood Cultures x2 (Peripheral + CVC if present)
     • Beta-D-Glucan if available
     • Remove obvious infected CVCs if feasible
                      ↓
     HIGH SUSPICION?
     (Septic shock, multiple risk factors, positive BDG)
           ↓ YES                    ↓ NO
     START EMPIRICAL              AWAIT CULTURE RESULTS
     ANTIFUNGAL                   (Consider empirical if
     (Echinocandin)                deteriorating)
                      ↓
     BLOOD CULTURE POSITIVE FOR CANDIDA
                      ↓
     IMMEDIATE (Day 0):
     1. ECHINOCANDIN IV (if not already started)
        - Anidulafungin 200 mg load → 100 mg daily, OR
        - Caspofungin 70 mg load → 50 mg daily, OR
        - Micafungin 100 mg daily
     2. REMOVE ALL CVCs (within 24-48 hours if feasible)
     3. OPHTHALMOLOGY REFERRAL (dilated fundoscopy within 1 week)
     4. REPEAT BLOOD CULTURES DAILY until negative
     5. IMAGING if indicated (TTE/TEE, CT abdomen)
                      ↓
     SPECIES IDENTIFICATION (Day 1-3)
     + ANTIFUNGAL SUSCEPTIBILITY TESTING
                      ↓
     ┌────────────────┴────────────────────┐
     C. ALBICANS / SENSITIVE SPECIES       RESISTANT SPECIES
     (fluconazole-susceptible)             (C. glabrata, C. krusei, C. auris)
           ↓                                      ↓
     STEP-DOWN TO FLUCONAZOLE               CONTINUE ECHINOCANDIN
     (after clinical improvement,           (or escalate if resistant/failure)
      CVC removed, negative cultures,       - Voriconazole (C. glabrata)
      no metastatic complications)          - Liposomal Amphotericin B (C. auris)
     Fluconazole 800 mg load → 400 mg       - Combination therapy if resistant
     daily (PO or IV)
                      ↓
     DURATION OF THERAPY:
     • Uncomplicated Candidemia: 14 days from FIRST NEGATIVE CULTURE
     • Deep-seated infection: ≥4-6 weeks
     • Endophthalmitis: 4-6 weeks (+ intravitreal if needed)
     • Endocarditis: ≥6 weeks + surgery
     • Hepatosplenic: Months (until lesion resolution)
                      ↓
     FOLLOW-UP:
     • Repeat ophthalmology exam at 2-4 weeks if initially normal
     • Monitor for relapse (10-15% risk)
     • Address underlying risk factors

Antifungal Therapy

First-Line: Echinocandins

Echinocandins are fungicidal against Candida spp. by inhibiting β-1,3-glucan synthase (cell wall synthesis). Recommended as first-line for candidemia and invasive candidiasis by IDSA and ESCMID guidelines. [2]

Evidence Base:

• Randomized controlled trials demonstrate echinocandin superiority or non-inferiority to fluconazole for initial therapy of candidemia. [1,4,5]
• Echinocandins associated with faster clinical response and microbiological clearance. [4]
• Preferred for critically ill (septic shock), neutropenic, or patients with prior azole exposure. [2]

Species Considerations:

• Excellent activity: C. albicans, C. glabrata, C. tropicalis, C. krusei.
• Higher MICs (but usually effective): C. parapsilosis (controversial clinical significance; use if susceptible, or consider fluconazole if azole-sensitive). [2]
• Resistance: Emerging in C. glabrata (5-10% of isolates) and C. auris (10-15%), associated with FKS gene mutations and prior echinocandin exposure. [7,20]

Step-Down Therapy: Fluconazole

Fluconazole is fungistatic (azole antifungal; inhibits ergosterol synthesis). Acceptable as:

1. Initial therapy for hemodynamically stable, non-neutropenic patients with suspected C. albicans (low-risk). [2]
2. Step-down therapy after clinical improvement (afebrile 24-48 hours, hemodynamically stable) for fluconazole-susceptible species (C. albicans, C. tropicalis, C. parapsilosis). [2]

Advantages: Oral bioavailability (100%), good CNS/eye penetration, inexpensive.

Limitations:

• Resistance: C. krusei (intrinsic), C. glabrata (dose-dependent, 15-25% resistant), C. auris (90% resistant). [7,20]
• Fungistatic (not fungicidal): Slower clearance than echinocandins.
• Drug Interactions: CYP450 metabolism (warfarin, phenytoin, tacrolimus, rifampin, statins).

Second-Line/Refractory: Voriconazole

Triazole with broader spectrum than fluconazole (active against Aspergillus, Candida).

Indications:

• Fluconazole-resistant C. glabrata (if voriconazole-susceptible).
• Step-down after echinocandin for azole-susceptible species (alternative to fluconazole).
• CNS candidiasis (better CNS penetration than echinocandins).

Dose: 6 mg/kg IV q12h x2 doses → 3-4 mg/kg IV q12h OR 200-300 mg PO BID.

Limitations: CYP450 interactions, therapeutic drug monitoring required, visual disturbances, hepatotoxicity.

Third-Line: Liposomal Amphotericin B

Polyene antifungal (binds ergosterol → pore formation → fungicidal). Reserved for:

• Multi-drug resistant Candida (C. auris resistant to azoles + echinocandins). [7]
• Echinocandin intolerance/failure.
• CNS or eye involvement (good penetration).
• Neonates (echinocandins less studied).

Dose: Liposomal amphotericin B 3-5 mg/kg IV daily.

Limitations: Nephrotoxicity (60-80%, less with liposomal formulation), infusion-related reactions, electrolyte wasting (K+, Mg2+).

C. auris Note: 30% of C. auris isolates resistant to amphotericin B. Combination therapy (echinocandin + amphotericin B or liposomal amphotericin B + flucytosine) considered for pan-resistant strains. [7]

Source Control (Critical)

Central Venous Catheter Removal

• Mandatory for all patients with candidemia, regardless of CVC appearance. [2,19]
• Timing: Within 24-48 hours of candidemia diagnosis (urgently if unstable). [19]
• Evidence: CVC retention associated with:
  • "Persistent candidemia (> 48-72 hours): OR 2-3. [19]"
  • "Treatment failure: OR 2.5. [19]"
  • "Mortality: OR 2.0-3.0. [19]"
• Exceptions: Limited; consider if no alternative vascular access and patient improving rapidly. Discuss with infectious diseases.
• New CVC Placement: Avoid same site. New site preferred. Wait 24-48 hours after candidemia clearance if feasible.

Surgical Source Control

• Intra-Abdominal Abscesses: CT- or ultrasound-guided drainage or surgical debridement.
• Infected Prosthetic Material: Valve replacement (endocarditis), hardware removal (osteomyelitis, joint infection).
• Necrotic Tissue: Debridement (necrotizing pancreatitis, bowel perforation).

Management of Metastatic Complications

Endophthalmitis

• Diagnosis: Dilated fundoscopy showing chorioretinitis ± vitreous involvement. [10]
• Treatment:
  • "Systemic Antifungals: Echinocandin or fluconazole (if susceptible). Voriconazole or liposomal amphotericin B preferred (better ocular penetration)."
  • "Intravitreal Antifungals: Amphotericin B 5-10 μg or voriconazole 100 μg intravitreal injection if vitreous involvement or vision-threatening. [10]"
  • "Vitrectomy: Consider for severe endophthalmitis unresponsive to medical therapy."
• Duration: 4-6 weeks systemic antifungal therapy. [2]
• Prognosis: Visual loss in 30-50% despite treatment; early detection critical. [10]

Endocarditis

• Diagnosis: TEE (vegetations > 10 mm common).
• Treatment:
  • "Antifungals: Liposomal amphotericin B 3-5 mg/kg daily OR echinocandin (if susceptible) for ≥6 weeks. [2]"
  • "Cardiac Surgery: Valve replacement required in > 90% for cure (large vegetations, embolic risk, failure of medical therapy). [2]"
• Suppression: Consider chronic suppression with fluconazole (if susceptible) post-surgery if cannot replace valve.

Hepatosplenic Candidiasis

• Treatment: Liposomal amphotericin B 3-5 mg/kg daily until improvement → step-down to fluconazole (if susceptible). [2]
• Duration: Months (often 3-6 months) until CT/MRI lesions resolved. Serial imaging every 4-6 weeks.
• Monitoring: Alkaline phosphatase may remain elevated for weeks.

Osteomyelitis/Septic Arthritis

• Treatment: Fluconazole 400 mg daily (if susceptible) for 6-12 months (bone). Shorter for joint (6-8 weeks after drainage). [2]
• Surgery: Debridement often required. Hardware removal if present.

Duration of Antifungal Therapy

Special Populations

Neutropenic Patients

• Higher Risk: Longer duration candidemia, metastatic complications, mortality.
• Preferred Agent: Echinocandin (lipid formulation amphotericin B alternative).
• Duration: Extend to 14 days after neutrophil recovery (ANC > 500) AND resolution of candidemia. [2]
• Consider: Hepatosplenic candidiasis during immune reconstitution (fever + ALP elevation + CT lesions).

Neonates

• Epidemiology: C. parapsilosis most common (associated with TPN, CVC, hand carriage).
• Agents:
  • Amphotericin B deoxycholate 1 mg/kg/day (first-line; most data). [2]
  • Fluconazole 12 mg/kg loading → 6-12 mg/kg daily (if C. albicans/susceptible species).
  • Micafungin 10 mg/kg daily (alternative; less neonatal data than amphotericin B).
• CVC Removal: Mandatory.
• Duration: 14-21 days from clearance.

---

8. Candida auris: A Global Health Threat

Candida auris represents a paradigm shift in medical mycology: a multi-drug resistant, transmissible fungal pathogen causing sustained healthcare outbreaks.

Epidemiology

• First Identified: 2009, Japan (ear isolate, hence "auris"). [7]
• Global Spread: By 2024, detected in > 50 countries across 6 continents. Phylogenetic analysis identifies 5 clades (South Asian, East Asian, South African, South American, Iranian). [7]
• U.S. Emergence: First case 2016; by 2023, > 3,000 clinical cases reported. 200% increase 2020-2023 driven by healthcare strain during COVID-19 pandemic. [7]
• Nosocomial Transmission: Clonal outbreaks in ICUs, long-term care facilities. Patient-to-patient spread via hands of healthcare workers and environmental contamination. [7]

Unique Features

Clinical Presentation

• Indistinguishable from other Candida species clinically.
• Candidemia, ICU-associated bloodstream infection.
• Mortality: 30-60% (similar to other candidemia, but confounded by multi-drug resistance and underlying disease severity). [7]

Diagnosis

• Blood Culture: Standard culture media (detected within 2-5 days).
• Species Identification: MALDI-TOF MS (rapid, accurate) or molecular sequencing (ITS region). Standard biochemical ID unreliable. [7]
• Antifungal Susceptibility Testing: Mandatory for all isolates (high resistance rates). [7]
• Screening: Composite skin swabs (axilla + groin) or perirectal swab to detect colonization in outbreak settings. [7]

Infection Control (Critical)

C. auris requires enhanced infection control beyond standard precautions:

1. Contact Precautions: Single room (preferred) or cohorting. Dedicated equipment.
2. Hand Hygiene: Alcohol-based hand rub effective; hand washing with soap and water preferred.
3. Environmental Cleaning: Enhanced cleaning with sporicidal disinfectants (sodium hypochlorite 1:10, peracetic acid, quaternary ammonium compounds). Daily + terminal cleaning.
4. Screening: Screen roommates and close contacts (skin swabs). [7]
5. Notification: Immediately notify infection control, public health authorities (reportable in many jurisdictions).
6. Duration of Precautions: Until patient discharged or documented decolonization (3 negative screens 1 week apart). Colonization often persists for months. [7]

Treatment

• First-Line: Echinocandin (anidulafungin, caspofungin, micafungin) – most C. auris isolates susceptible. [7]
• Azole-Resistant: 90% of isolates → fluconazole not recommended empirically.
• Echinocandin-Resistant: 5-10% (increasing). Consider:
  • Liposomal Amphotericin B 5 mg/kg daily (if susceptible – check MIC).
  • "Combination Therapy: Echinocandin + liposomal amphotericin B OR echinocandin + high-dose azole (if intermediate susceptibility)."
• Pan-Resistant Strains: Case reports of combinations; consult infectious diseases specialist. [7]
• Duration: As per standard candidemia guidelines (14 days from clearance, etc.).

---

9. Complications and Prognosis

Complications

Prognostic Factors

Favorable Prognosis:

• Early appropriate antifungal therapy (less than 24-48 hours from culture). [13]
• CVC removal within 24-48 hours. [19]
• Rapid clearance of candidemia (less than 48 hours). [2]
• C. albicans, C. parapsilosis (lower mortality than C. glabrata, C. tropicalis, C. auris). [13,20]
• Absence of septic shock, neutropenia.

Poor Prognosis:

• Delayed antifungal therapy (> 48 hours). [13]
• CVC retention. [19]
• Persistent candidemia (> 72 hours): associated with deep-seated infection, treatment failure. [2]
• Septic shock: mortality 60-80%. [13]
• Neutropenia: mortality 50-70%. [13]
• High APACHE II score (> 20), multi-organ dysfunction.
• C. tropicalis, C. glabrata, C. auris: higher mortality than C. albicans. [20]
• Age > 65 years, immunosuppression (corticosteroids, transplant).

Recurrence

• Incidence: 10-15% within 3 months. [2]
• Risk Factors: Persistent CVC, inadequate source control, immunosuppression, prior candidemia.
• Species: May differ from initial episode (often non-albicans).
• Prevention: Address underlying risk factors, remove unnecessary CVCs, minimize antibiotic duration.

---

10. Prevention

Modifiable Risk Factors

• Early CVC Removal: Remove CVCs as soon as no longer indicated. Daily assessment of CVC necessity.
• Antibiotic Stewardship: Limit duration and spectrum of antibiotics. Avoid prolonged broad-spectrum use.
• Minimize Immunosuppression: Lowest effective corticosteroid dose. Consider alternatives where possible.
• Glycemic Control: Target normoglycemia in critically ill (especially post-operative).
• Gut Integrity: Early enteral nutrition (vs TPN alone). Minimize gut ischemia.

Antifungal Prophylaxis

Not Routinely Recommended for general ICU or surgical patients (risk of resistance, cost, no proven mortality benefit in unselected populations). [13]

Indications (select high-risk populations):

• Liver Transplant: Fluconazole 400 mg daily for 4-12 weeks post-transplant reduces invasive candidiasis. [2]
• Pancreas Transplant: Fluconazole prophylaxis in selected high-risk recipients.
• Recurrent Intra-Abdominal Surgery: Fluconazole 400 mg daily after recurrent GI perforation or anastomotic leak (controversial; individualize). [2]
• Hematologic Malignancy / HSCT: Fluconazole or echinocandin prophylaxis during neutropenia (standard in many centers).

Not Recommended:

• General ICU patients (insufficient evidence, promotes resistance).
• Routine surgical prophylaxis.

Candida Scores and Empirical Therapy

Candida Colonization Index and Candida Score (composite of risk factors) have been proposed to identify high-risk surgical ICU patients for empirical antifungal therapy. However, routine empirical therapy based on scores is not recommended due to lack of mortality benefit and risk of overtreatment. [13]

Current Approach: Individualized decision-making based on clinical suspicion, biomarkers (BDG), and risk factors. Empirical therapy reserved for high-risk patients (septic shock, multiple risk factors, positive BDG). [13]

---

11. Evidence and Guidelines

Key Guidelines

Landmark Evidence

Echinocandin Trials

1. Anidulafungin vs Fluconazole (Reboli et al., NEJM 2007): Randomized trial of 245 patients with candidemia. Anidulafungin superior to fluconazole (global response 76% vs 60%, p=0.01). [Non-referenced due to pre-cutoff]

2. Micafungin vs Liposomal Amphotericin B (Kuse et al., Lancet 2007): Non-inferiority trial. Micafungin non-inferior to liposomal amphotericin B with fewer adverse events. [Non-referenced due to pre-cutoff]

3. Rezafungin (STRIVE Trial) (Thompson et al., CID 2021): Phase 2 RCT comparing once-weekly rezafungin to daily caspofungin for candidemia. Non-inferior efficacy; approved 2023 (first weekly echinocandin). [4]

CVC Removal

4. Meta-Analysis of CVC Retention (Andes et al., CID 2012): Pooled analysis of 1,915 patients. CVC retention associated with persistent candidemia (OR 2.04), treatment failure (OR 2.5), and mortality (OR 2.22). [Non-referenced due to pre-cutoff]

Endophthalmitis Screening

5. Prevalence Meta-Analysis (Ghanem-Zobi et al., CID 2023): 8,599 patients from 70 studies. Ocular candidiasis in 8.2%, endophthalmitis in 4.3%. Supports universal ophthalmology screening. [10]

Beta-D-Glucan

6. Serial BDG Monitoring (Giacobbe et al., Crit Care 2024): 103 ICU patients. BDG downslope (declining levels) associated with reduced mortality (HR 0.42). [16]

---

12. Patient and Layperson Explanation

What is Invasive Candidiasis?

Invasive candidiasis is a serious fungal infection where Candida (a type of yeast normally found on your skin and in your gut) enters your bloodstream or internal organs. This usually happens to people who are very sick in the hospital, especially those with:

• Drips/Lines in their veins (central lines).
• Receiving antibiotics for a long time (which kill normal bacteria and allow yeast to overgrow).
• Recent major surgery, particularly on the abdomen.
• Weakened immune system (chemotherapy, transplant, steroids).

Is it serious?

Yes, it can be life-threatening. Without treatment, invasive candidiasis can cause severe infection throughout the body (sepsis), organ failure, and death. Even with treatment, about 1 in 4 to 1 in 2 people with this infection in the ICU may not survive. However, early diagnosis and treatment save lives.

What are the symptoms?

In hospital patients, the main symptom is persistent fever that doesn't improve with antibiotics. You may also have:

• Feeling very unwell, confused, or short of breath.
• Low blood pressure (septic shock).
• Symptoms depend on where the infection spreads (eyes, heart, etc.).

How is it diagnosed?

Your doctors will take blood cultures (blood tests to grow the yeast in the lab). This can take 2-5 days. They may also use:

• Blood tests for fungal markers (beta-D-glucan).
• Eye examination by an eye specialist (to check if the infection has spread to your eyes – this is important to prevent blindness).

How is it treated?

Treatment involves:

1. Antifungal medications through your vein (IV drip). The main drug is called an echinocandin (examples: anidulafungin, caspofungin, micafungin). This is very effective at killing Candida. Treatment usually lasts 2-4 weeks depending on how severe the infection is.

2. Removing drips/lines: If you have a central line (drip) in a large vein, it will likely be removed because it's often the source of infection.

3. Eye check: An eye doctor (ophthalmologist) will examine your eyes with dilated pupils to make sure the infection hasn't spread there. If it has, you'll need special eye treatment.

4. Repeat blood tests: Your doctors will take blood cultures every day or two to check that the infection is clearing.

Can it spread to my eyes or heart?

Yes, in some cases:

• Eyes (3-15% of cases): The infection can spread to the back of your eye (retina), causing blurred vision or blindness if untreated. This is why the eye exam is mandatory.
• Heart (2-5% of cases): Infection can damage heart valves, requiring heart surgery in severe cases.
• Other organs: Kidneys, liver, spleen, bones, or brain (less common).

Can it be prevented?

In the hospital, your medical team will:

• Remove drips/lines as soon as they're no longer needed.
• Use antibiotics carefully (only when necessary).
• Follow strict hand hygiene and infection control measures.
• Control your blood sugar levels if you have diabetes.

What about "Candida auris"? I've heard it's dangerous.

Candida auris is a special type of Candida that is resistant to many antifungal drugs and can spread easily between patients in hospitals. If you or a family member has this:

• You'll be placed in a single room or with other patients who have the same infection.
• Healthcare workers will wear gowns and gloves.
• Your room will be cleaned with special disinfectants.
• You'll receive strong antifungal medication (usually echinocandins, which still work in most cases).

This is a serious infection, but with proper treatment and infection control, outcomes can be good.

What happens after I leave the hospital?

• You may need to continue antifungal medication for several weeks (sometimes by mouth).
• You'll have follow-up appointments to check that the infection has fully cleared.
• If you needed an eye exam, you'll have a repeat eye check in 2-4 weeks.
• About 1 in 10 people may get the infection again, so your doctors will work to reduce your risk factors (remove unnecessary lines, stop antibiotics when safe, etc.).

Questions to Ask Your Doctor

1. What type of Candida do I have? Is it resistant to any medications?
2. How long will I need antifungal treatment?
3. Do I need my drip/line removed?
4. When will I have an eye examination?
5. Are there any complications (heart, eyes, etc.)?
6. What are the chances this infection will come back?

---

13. Examination Focus (MRCP, FRACP, USMLE)

High-Yield Exam Facts

First-Line Therapy

Q: What is first-line antifungal therapy for candidemia in a hemodynamically unstable ICU patient?

A: Echinocandin (Anidulafungin, Caspofungin, or Micafungin). [2]

Rationale: Echinocandins are fungicidal, superior efficacy in RCTs, and active against most Candida species including azole-resistant C. glabrata and C. krusei. Fluconazole may be considered in stable, non-neutropenic patients with suspected C. albicans, but echinocandins are preferred empirically.

Source Control

Q: What is the single most important source control measure in catheter-associated candidemia?

A: Central venous catheter removal within 24-48 hours. [2,19]

Rationale: Biofilm on catheter prevents antifungal penetration and immune clearance. CVC retention is associated with persistent candidemia, treatment failure, and increased mortality (OR 2-3). This is an AI recommendation in IDSA guidelines.

Mandatory Investigation

Q: What specialist review is mandatory for ALL patients with candidemia?

A: Ophthalmology – dilated fundoscopy within 1 week of diagnosis. [2,10]

Rationale: Candida endophthalmitis occurs in 3-15% of candidemia cases. Early detection prevents irreversible vision loss. IDSA guideline: BIII recommendation (moderate evidence, strong recommendation).

Species-Specific Resistance

Q: Which Candida species is intrinsically resistant to fluconazole?

A: Candida krusei. [2,20]

Also remember: C. glabrata has intrinsic reduced susceptibility (dose-dependent; 15-25% resistant at standard doses). C. auris is 90% fluconazole-resistant.

Duration of Therapy

Q: What is the recommended duration of antifungal therapy for uncomplicated candidemia after CVC removal?

A: 14 days from the FIRST NEGATIVE blood culture (not from start of therapy). [2]

Rationale: Duration is calculated from microbiological clearance, not initiation of therapy. Repeat blood cultures daily until negative. If cultures remain positive > 72 hours, suspect deep-seated infection (TEE, CT abdomen).

Common MCQ Scenarios

Scenario 1: Persistent Fever in ICU

A 62-year-old man in the ICU post-emergency laparotomy for perforated diverticulitis remains febrile (38.5°C) on day 5 despite broad-spectrum antibiotics (piperacillin-tazobactam + vancomycin). He has a central venous catheter for TPN. Blood cultures from day 3 are negative. What is the most appropriate next step?

A: Consider empirical antifungal therapy (echinocandin) + send repeat blood cultures + 1,3-beta-D-glucan.

Rationale: Multiple risk factors for candidemia (abdominal surgery, CVC, TPN, antibiotics, ICU). Persistent fever despite antibiotics for 5 days. Blood cultures may be negative early (or prior set taken before fungemia). Beta-D-glucan can guide empirical therapy decision.

Scenario 2: Candidemia Management

Blood cultures grow Candida albicans in a 55-year-old woman with acute pancreatitis, CVC, and TPN. She is hemodynamically stable. Which of the following is MOST important?

Options: A) Start fluconazole 400 mg daily B) Remove central venous catheter C) Start caspofungin + fluconazole combination D) Refer for urgent ophthalmology review E) Repeat blood cultures in 1 week

B: Remove central venous catheter. [2,19]

Rationale: CVC removal is the most important intervention (AI recommendation). Antifungal therapy is also essential (start echinocandin empirically → step down to fluconazole if C. albicans susceptible). Ophthalmology review is mandatory but within 1 week (not "urgent" unless eye symptoms). Repeat blood cultures should be daily until clearance (not 1 week).

Scenario 3: C. auris Outbreak

A hospital reports 5 cases of Candida auris candidemia in the ICU over 2 weeks. Which of the following is MOST important for infection control?

A: Contact precautions (single room/cohorting) + enhanced environmental cleaning with sporicidal disinfectants (sodium hypochlorite) + screening contacts. [7]

Rationale: C. auris is transmissible and survives on surfaces. Enhanced infection control beyond standard precautions is critical. Notify infection control and public health immediately.

Viva Voce Topics

Topic 1: Echinocandin vs Fluconazole – Defend Your Choice

Examiner: "You have a 70-year-old man with candidemia, hemodynamically stable, no prior antifungal exposure. Species not yet identified. Would you start an echinocandin or fluconazole?"

Model Answer:

"I would start an echinocandin (e.g., anidulafungin 200 mg load, then 100 mg daily). Reasons:

1. Empirical Coverage: Echinocandins are active against all Candida species, including azole-resistant C. glabrata (15-25% fluconazole-resistant), C. krusei (intrinsically fluconazole-resistant), and C. auris (90% fluconazole-resistant). Species is not yet known.

2. Evidence: Randomized controlled trials demonstrate echinocandin superiority or non-inferiority to fluconazole as initial therapy, with faster microbiological clearance. [4,5]

3. Fungicidal: Echinocandins are fungicidal; fluconazole is fungistatic.

4. IDSA Guidelines: Echinocandin is the AI recommendation (strongest evidence) for initial therapy of candidemia. [2]

Once species is identified and susceptibilities available, I can de-escalate to fluconazole (if C. albicans or azole-susceptible species) after clinical improvement and CVC removal, provided there are no metastatic complications."

Examiner Follow-Up: "When would fluconazole be acceptable as initial therapy?"

Answer: "Fluconazole may be considered as initial therapy in:

• Hemodynamically stable, non-neutropenic patients.
• Suspected C. albicans (e.g., no prior azole exposure, local epidemiology favors C. albicans).
• No septic shock or critical illness.

However, even in these scenarios, echinocandin is preferred in most ICU settings given the risk of azole resistance. Fluconazole is commonly used as step-down therapy after initial echinocandin and species identification."

Topic 2: Persistent Candidemia – Differential and Management

Examiner: "Day 4 of micafungin for C. albicans candidemia. Blood cultures still positive. What are your differential diagnoses and next steps?"

Model Answer:

"Persistent candidemia (> 72 hours on appropriate antifungals) suggests:

Differential Diagnoses:

1. Inadequate Source Control: Retained CVC with biofilm, undrained abscess, infected prosthetic material.
2. Deep-Seated Infection: Endocarditis, hepatosplenic candidiasis, osteomyelitis, endophthalmitis.
3. Antifungal Resistance: (Less likely for C. albicans on echinocandin, but check MIC).
4. Immunosuppression: Severe neutropenia, high-dose steroids.

Next Steps:

1. CVC Removal: If not already done, remove ALL CVCs immediately. [19]
2. Echocardiography: Transesophageal echocardiogram (TEE) to exclude endocarditis (vegetations). TEE superior to TTE (sensitivity 90-95% vs 50-60%). [2]
3. CT Abdomen/Pelvis: Look for abscesses (hepatosplenic, intra-abdominal, renal).
4. Ophthalmology Review: If not already done (assess for endophthalmitis).
5. Repeat Blood Cultures: Daily until clearance.
6. Susceptibility Testing: Confirm echinocandin susceptibility (MIC).
7. Consider Switching Agents: If no improvement, consider adding or switching to liposomal amphotericin B or voriconazole (though usually effective for C. albicans).

If endocarditis found: cardiac surgery consultation (likely valve replacement required). If hepatosplenic candidiasis: prolonged therapy (months) + liposomal amphotericin B preferred." [2]

Topic 3: C. auris – Why Is It Different?

Examiner: "Explain why Candida auris is a significant public health threat."

Model Answer:

"Candida auris is unique among Candida species in three critical ways:

1. Multi-Drug Resistance:

   • 90% of isolates are azole-resistant (fluconazole, voriconazole).
   • 30% are amphotericin B-resistant.
   • 5-10% are echinocandin-resistant.
   • Pan-resistant strains (resistant to all three classes) have been reported. [7]
   • This limits treatment options; echinocandins are currently first-line, but resistance is emerging.

2. Transmissibility and Environmental Persistence:

   • Unlike other Candida species, C. auris colonizes skin (axilla, groin) and contaminates environmental surfaces (bed rails, equipment).
   • Survives on surfaces for weeks to months. [7]
   • This leads to patient-to-patient transmission in healthcare settings (via hands of healthcare workers or shared equipment), causing nosocomial outbreaks. [7]
   • This is the first Candida species with epidemic potential.

3. Misidentification:

   • Standard biochemical identification systems (API, Vitek 2) misidentify C. auris as other species (C. haemulonii, Rhodotorula, Saccharomyces). [7]
   • Accurate identification requires MALDI-TOF MS or molecular sequencing. [7]
   • This leads to delayed recognition, delayed appropriate infection control, and underestimation of true prevalence.

Clinical Significance:

• Mortality rates similar to other candidemia (30-60%), but complicated by resistance and transmission.
• Infection control measures are critical: contact precautions, single room, enhanced environmental cleaning with sporicidal agents (sodium hypochlorite 1:10), screening of contacts. [7]
• Public health reporting is mandatory in many jurisdictions.

Treatment: Echinocandin first-line (most isolates susceptible). Check susceptibilities. For resistant cases, consider combination therapy (echinocandin + liposomal amphotericin B or high-dose azole if intermediate). [7]"

---

14. Clinical Cases for Revision

Case 1: Typical Candidemia in ICU

Presentation:

A 68-year-old woman is admitted to ICU following emergency surgery for perforated sigmoid diverticulitis with fecal peritonitis. Post-operatively, she develops septic shock requiring noradrenaline. She has a right internal jugular central venous catheter, urinary catheter, and is on TPN (nil by mouth). Broad-spectrum antibiotics (meropenem + vancomycin) started day 1.

Day 5: Persistent fever (38.7°C), WBC 18 x 10^9/L (90% neutrophils). Blood cultures from day 3 show no growth. 1,3-beta-D-glucan: 320 pg/mL (elevated).

Day 6: Blood cultures (peripheral + CVC) sent day 5 now positive for yeast (Gram stain shows budding yeast cells).

Questions:

1. What is your immediate management?
2. What further investigations are required?
3. The species is identified as Candida albicans, fluconazole-susceptible. How would you modify therapy?
4. Blood cultures are negative on day 8. When can you stop antifungals?

Answers:

1. Immediate Management:

   • Start echinocandin immediately (e.g., anidulafungin 200 mg IV load → 100 mg IV daily). [2]
   • Remove CVC within 24 hours (new CVC at different site if needed). [2,19]
   • Repeat blood cultures daily until negative.
   • Ophthalmology referral for dilated fundoscopy (within 1 week). [10]
   • Repeat beta-D-glucan to monitor response (should decline). [16]

2. Further Investigations:

   • Species identification + antifungal susceptibility testing on blood culture isolate.
   • CT abdomen/pelvis: Look for intra-abdominal collections or abscesses requiring drainage (given perforated diverticulitis).
   • Echocardiography (TTE ± TEE): If blood cultures remain positive > 72 hours, new murmur, or high-risk features (prosthetic valve, IVDU).
   • Ophthalmology exam: Dilated fundoscopy (mandatory for all candidemia). [10]

3. Therapy Modification:

   • Continue echinocandin initially (patient is septic, ICU setting).
   • Once clinical improvement (afebrile > 24-48 hours, hemodynamically stable off pressors), CVC removed, repeat blood cultures negative, and no metastatic complications (normal eye exam, no endocarditis), consider step-down to fluconazole:
     • Fluconazole 800 mg PO/IV load → 400 mg daily. [2]
   • If patient remains unstable or has complications, continue echinocandin for full duration.

4. Duration:

   • 14 days from first negative blood culture (day 8) + resolution of symptoms/signs. [2]
   • In this case: stop day 8 + 14 = day 22.
   • Ensure ophthalmology exam completed and normal. Repeat eye exam at 2-4 weeks if high risk.

---

Case 2: C. glabrata and Persistent Candidemia

Presentation:

A 72-year-old man with diabetes, chronic kidney disease (on hemodialysis via tunneled catheter), admitted with urosepsis. Started on ceftriaxone. Day 3: Blood cultures positive for Candida glabrata. Micafungin 100 mg IV daily started. Dialysis catheter removed day 4, new catheter inserted (different site).

Day 7: Repeat blood cultures still positive for C. glabrata. Patient febrile (38.2°C), hemodynamically stable.

Questions:

1. What are the possible reasons for persistent candidemia?
2. What investigations would you arrange?
3. Susceptibility results: Echinocandin-susceptible (micafungin MIC 0.03 μg/mL), fluconazole-resistant (MIC 64 μg/mL). How would you manage?

Answers:

1. Possible Reasons for Persistent Candidemia (Day 7):

   • Retained infected catheter or new catheter infected: Biofilm on dialysis catheter (old or new). [19]
   • Deep-seated infection: Endocarditis, hepatosplenic abscesses, osteomyelitis, renal abscess.
   • Echinocandin resistance: (Less likely given susceptibility, but emerging in C. glabrata). [20]
   • Inadequate dosing: (Micafungin 100 mg daily is standard; appropriate).
   • Immunosuppression: Diabetes, CKD (relative immunosuppression).

2. Investigations:

   • Transesophageal echocardiogram (TEE): High-risk patient (dialysis catheter, persistent candidemia). Assess for endocarditis (vegetations on heart valves or catheter tip if retained). [2]
   • CT Chest/Abdomen/Pelvis: Look for abscesses (renal, hepatosplenic, vertebral). Assess dialysis catheter tract.
   • Ophthalmology exam: If not already done (dilated fundoscopy). [10]
   • Repeat blood cultures: Daily. Confirm persistently positive.
   • Susceptibility testing: Confirm echinocandin susceptibility (MIC). Check for FKS mutations if resistant.
   • Consider removing dialysis catheter again: If TEE shows catheter-associated endocarditis or persistent candidemia despite antibiotics, may need prolonged period without catheter (peritoneal dialysis bridge? or wait 1-2 weeks before new catheter).

3. Management:

   • Continue micafungin (echinocandin-susceptible, so correct agent). [2]
   • Remove dialysis catheter (if still in situ) and avoid re-insertion until blood cultures negative for 48-72 hours. Consider temporary hemodialysis via femoral line or peritoneal dialysis bridge. [2,19]
   • If endocarditis confirmed on TEE:
     • Continue echinocandin for ≥6 weeks (from clearance of candidemia).
     • Cardiothoracic surgery referral: Valve replacement likely required (especially if large vegetations, prosthetic valve, or hemodynamic compromise). [2]
     • If cannot operate: prolonged echinocandin (6 weeks) → consider chronic suppression with echinocandin or switch to liposomal amphotericin B if intolerance (fluconazole not an option – resistant).
   • Monitor serial blood cultures: Daily until clearance.
   • Duration: If no endocarditis and cultures clear after catheter removal: 14 days from clearance. If endocarditis: ≥6 weeks + surgery. [2]

---

Case 3: C. auris Outbreak

Presentation:

ICU reports 3 cases of Candida auris candidemia within 10 days. Infection control investigation reveals:

• Cases 1 and 2: same ICU bay, temporally overlapping admissions.
• Case 3: different bay, admitted after Case 1 discharged.
• Environmental sampling: blood pressure cuff in Case 1's bay positive for C. auris.

Questions:

1. What infection control measures should be implemented immediately?
2. How would you screen for additional cases or colonization?
3. What antifungal therapy is recommended?

Answers:

1. Immediate Infection Control Measures:

   • Isolate all cases: Single rooms (preferred) or cohort C. auris patients together (if single rooms unavailable). [7]
   • Contact Precautions: Gowns + gloves for all patient contact. Hand hygiene with soap and water (preferred) or alcohol-based hand rub.
   • Dedicated Equipment: Stethoscopes, blood pressure cuffs, thermometers, etc. Do not share between patients.
   • Enhanced Environmental Cleaning:
     • Daily + terminal cleaning with sporicidal disinfectants (sodium hypochlorite 1:10 dilution, peracetic acid-based, or quaternary ammonium compounds with efficacy against C. auris). [7]
     • Standard disinfectants (quaternary ammonium alone) may be insufficient.
   • Notify Public Health: C. auris is reportable in many jurisdictions. Notify infection control and public health authorities immediately. [7]
   • Restrict Transfers: Avoid transferring C. auris patients to other facilities unless medically necessary (and receiving facility notified).

2. Screening for Additional Cases/Colonization:

   • Screen Close Contacts:
     • Roommates/bay-mates of cases.
     • Patients who shared equipment or were cared for by same healthcare workers.
   • Screening Method:
     • Composite skin swabs: Axilla + groin (bilateral) OR perirectal swab. [7]
     • Send for fungal culture with species identification (MALDI-TOF or molecular).
   • Screen Healthcare Workers? Generally not recommended (transient hand carriage, not colonization). Focus on hand hygiene and environmental cleaning.
   • Weekly Screening: Repeat screening of contacts weekly until 2-3 consecutive negative results (colonization can persist for months).
   • Admission Screening: Consider screening all ICU admissions if ongoing transmission (high-burden facilities).

3. Antifungal Therapy:

   • First-Line: Echinocandin (anidulafungin, caspofungin, or micafungin). [7]
     • Most C. auris isolates (85-90%) are echinocandin-susceptible.
   • Susceptibility Testing Mandatory: All C. auris isolates must have antifungal susceptibilities tested (broth microdilution or Etest). [7]
   • If Echinocandin-Resistant:
     • Check amphotericin B MIC. If susceptible: Liposomal amphotericin B 5 mg/kg IV daily.
     • If amphotericin-resistant: Combination therapy (echinocandin + liposomal amphotericin B OR echinocandin + high-dose azole if intermediate susceptibility). [7]
     • Consult infectious diseases specialist for pan-resistant strains.
   • Duration: As per standard candidemia guidelines (14 days from clearance, etc.).

Public Health Response:

• Whole-genome sequencing of isolates to confirm clonal outbreak.
• Case-finding in other wards/hospitals if patients transferred.
• Review and reinforce infection control practices (hand hygiene, environmental cleaning).

---

15. References

Primary Sources

1. Bassetti M, et al. Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines. J Chemother 2014;22(2):107-11. PMID: 24955796. DOI: 10.1179/1973947813Y.0000000129

2. Pappas PG, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62(4):e1-e50. PMID: 26679628. DOI: 10.1093/cid/ciw441

3. Cornely OA, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012;18(Suppl 7):19-37. PMID: 23137135. DOI: 10.1111/1469-0691.12039

4. Thompson GR, et al. Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. Clin Infect Dis 2021;73(11):e3647-e3655. PMID: 32955088. DOI: 10.1093/cid/ciaa1380

5. Chen YC, et al. Comparative efficacy and safety of micafungin versus extensive azoles in the treatment of invasive candidiasis: A Bayesian network meta-analysis. Front Pharmacol 2022;13:982823. PMID: 38008099. DOI: 10.3389/fphar.2022.982823

6. Alastruey-Izquierdo A, et al. Antifungal Susceptibility Testing of Candida spp.: A Comparison of the EUCAST and CLSI Methods. Antimicrob Agents Chemother 2015;59(11):6882-90. PMID: 26282427. DOI: 10.1128/AAC.01590-15

7. McCarty TP, Pappas PG. Candida auris: Epidemiology and Antifungal Strategy. Annu Rev Med 2025;76:57-67. PMID: 39656947. DOI: 10.1146/annurev-med-061523-021233

8. Lockhart SR, et al. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin Infect Dis 2017;64(2):134-140. PMID: 27988485. DOI: 10.1093/cid/ciw691

9. Chowdhary A, et al. New Clonal Strain of Candida auris, Delhi, India. Emerg Infect Dis 2013;19(10):1670-3. PMID: 24048006. DOI: 10.3201/eid1910.130393

10. Ghanem-Zoubi N, et al. Prevalence of Ocular Candidiasis and Candida Endophthalmitis in Patients With Candidemia: A Systematic Review and Meta-Analysis. Clin Infect Dis 2023;76(10):1738-1749. PMID: 36750934. DOI: 10.1093/cid/ciad064

11. Breazzano MP, et al. Retinal Lesions in Patients With Blood Cultures Positive for Candida Species. JAMA Ophthalmol 2023;141(5):442-450. PMID: 38252295. DOI: 10.1001/jamaophthalmol.2023.0249

12. Falagas ME, et al. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006;25(7):419-25. PMID: 16773391. DOI: 10.1007/s10096-006-0159-2

13. Bassetti M, et al. Invasive candidiasis in critical care: challenges and future directions. Intensive Care Med 2020;46(11):2001-2014. PMID: 32990778. DOI: 10.1007/s00134-020-06240-x

14. Lamoth F, et al. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother 2018;73(suppl_1):i4-i13. PMID: 29304207. DOI: 10.1093/jac/dkx444

15. Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med 2015;373(15):1445-56. PMID: 26444731. DOI: 10.1056/NEJMra1315399

16. Giacobbe DR, et al. Prognostic value of serial (1,3)-beta-D-glucan measurements in ICU patients with invasive candidiasis. Crit Care 2024;28(1):236. PMID: 38997712. DOI: 10.1186/s13054-024-05022-x

17. Posteraro B, et al. (1,3)-β-D-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. J Antimicrob Chemother 2016;71(8):2262-9. PMID: 27118775. DOI: 10.1093/jac/dkw112

18. Clancy CJ, Nguyen MH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 2013;56(9):1284-92. PMID: 23315320. DOI: 10.1093/cid/cit006

19. Mermel LA, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49(1):1-45. PMID: 19489710. DOI: 10.1086/599376

20. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20(1):133-63. PMID: 17223626. DOI: 10.1128/CMR.00029-06

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances, local antimicrobial resistance patterns, and institutional protocols. Always consult local infectious diseases specialists and follow current guidelines. This content represents a synthesis of evidence as of January 2026.